TECHNIVIE Drug Patent Profile

Which patents cover Technivie, and what generic alternatives are available?

Technivie is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug.

This drug has three hundred and ninety-three patent family members in forty-six countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Technivie

Technivie was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TECHNIVIE

International Patents:	393
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECHNIVIE

US Patents and Regulatory Information for TECHNIVIE

TECHNIVIE is protected by six US patents.

This potential generic entry date is based on patent 8,691,938.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	8,642,538		Y	Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	8,686,026		Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	9,044,480
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	9,006,387
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	8,420,596*PED				Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	8,691,938		Y	Y

International Patents for TECHNIVIE

When does loss-of-exclusivity occur for TECHNIVIE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TECHNIVIE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3482762	FORMULATION DE DOSAGE PHARMACEUTIQUE SOLIDE COMPRENANT DU LOPINAVIR (A SOLID PHARMACEUTICAL DOSAGE FORMULATION COMPRISING LOPINAVIR)
Taiwan	I381840
Costa Rica	20140021	COMPUESTOS ANTIVIRALES
Guatemala	200600295	UNA FORMULACION SOLIDA DE DOSIFICACION FARMACEUTICA
Cyprus	1117188
Israel	185390	צורת מינון רוקחית מוצקה (Solid pharmaceutical dosage formulation)

Supplementary Protection Certificates for TECHNIVIE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2340029	SPC/GB15/014	United Kingdom		PRODUCT NAME: PARITAPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTERED: UK EU/1/14/982 20150119
2368890	15C0016	France		PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
2340029	599	Finland
2692346	17C1040	France		PRODUCT NAME: PIBRENTASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728
2692346	51/2017	Austria		PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 (MITTEILUNG) 20170728
2340029	2015/011	Ireland		PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115

Summary

Last updated: February 10, 2026

Technivie is a fixed-dose combination drug approved for the treatment of hepatitis C virus (HCV) in genotype 4 infection. Marketed primarily in the U.S., it faces competition from direct-acting antiviral (DAA) regimens that offer higher efficacy, shorter treatment durations, and favorable safety profiles. Investment in Technivie requires consideration of its patent exclusivity, market penetration, evolving treatment landscape, and regulatory environment.

---

What Are the Market Fundamentals for Technivie?

Approval and Indication

• Approved in 2015 by the FDA for genotype 4 HCV.
• Contains paritaprevir, ritonavir, ombitasvir.
• Dosed once daily for 12 to 24 weeks.

Market Size and Penetration

• Estimated global HCV prevalence: 58 million, with 13 million in the U.S.
• The U.S. represents a significant market due to high treatment demand.
• Technivie targeted primarily for genotype 4, a minority among HCV genotypes.

Market Competition

• Extremely competitive; major competitors include Gilead's Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Mavyret (glecaprevir/pibrentasvir).
• These competitors offer pan-genotypic coverage, shorter durations, and high cure rates.
• Technivie’s advantage diminished post-2017 with the approval of pan-genotypic regimens.

Patent and Exclusivity

• Patent protection extends approximately until 2025.
• Limited data suggests upcoming generic competition post-2025.

Pricing and Reimbursement

• Priced at approximately $39,000 per 12-week course, in line with DAA standards.
• Reimbursement largely depends on insurance coverage, Medicaid, and Medicare.

---

What Are the Drug Development and Regulatory Fundamentals?

Efficacy and Safety Data

• Clinical trials showed cure rates (SVR12) over 90% in genotype 4 patients.
• Tolerability profiles are similar to other DAAs, with low discontinuation rates.
• Data are limited compared to newer pan-genotypic drugs with broader indications.

Regulatory Pathways

• Approved via New Drug Application (NDA) in 2015.
• Post-approval, supplemental approvals for expanded populations are limited.
• Limited pipeline for major label extensions.

Patent Challenges

• Patent expiry expected around 2025.
• Ongoing patent litigation may impact marketing exclusivity.

---

What Is the Investment Outlook?

Strengths

• Established safety and efficacy profile.
• Market approval in key regions.

Weaknesses

• Narrow indication (genotype 4).
• Competition from pan-genotypic drugs reduces market share potential.
• Patent expiration approaching.

Opportunities

• Potential for lifecycle extension through label expansion into other genotypes.
• Development of combination therapies that include Technivie components.

Threats

• Incoming generic competition post-2025.
• Rapid evolution of HCV therapeutics favoring pan-genotypic regimens.
• Market shifts toward simplified, shorter treatment courses.

---

Key Takeaways

• Technivie’s current value is limited by its narrow genotype focus and imminent patent expiry.
• Its market position is under threat from competing pan-genotypic DAAs with broader indications.
• Long-term investment requires anticipation of patent expiration impacts and potential regulatory or pipeline developments.
• Strategic options include licensing partnerships, pipeline development for broader indications, or repositioning within combination therapies.

---

FAQs

1. How does Technivie compare to other hepatitis C treatments?
Technivie offers high efficacy in genotype 4 HCV but is less versatile than pan-genotypic regimens like Epclusa, which treat all genotypes in a shorter timeframe.

2. When will patent protection expire, and how does that impact investment?
Patent protection is expected to last until 2025, after which generic versions could significantly reduce revenues.

3. Are there opportunities for Technivie in markets outside the U.S.?
Potential exists in select regions with unmet needs for genotype 4 treatment; however, competition and regulatory hurdles exist.

4. What are regulatory risks for Technivie?
Risks include delays in approval for new indications and challenges to patent protections, which could accelerate fiscal decline.

5. Can pipeline development extend the product’s lifecycle?
Yes, if label expansions or combination therapies are approved, they could mitigate the impact of patent expiry and expand market share.

---

Citations

[1] U.S. Food and Drug Administration. FDA approval of Technivie (paritaprevir, ombitasvir, ritonavir). 2015.

[2] IQVIA. Global HCV drug market data. 2022.

[3] EvaluatePharma. Forecasts on hepatitis C drug sales. 2023.

[4] Gilead Sciences. Hepatitis C market analysis reports. 2022.

[5] PatentScope. Patent filings related to Technivie components. 2021.